Real-world study

Tezepelumab Demonstrates Robust Efficacy and Safety Across Diverse Severe Asthma Phenotypes: Insights from the Phase 4 PASSAGE Study

The PASSAGE phase 4 study reveals tezepelumab significantly reduces exacerbation rates and improves lung function and quality of life in a broad US severe asthma population, including underrepresented groups and varied phenotypes.